<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331835</url>
  </required_header>
  <id_info>
    <org_study_id>LP0160-1327</org_study_id>
    <secondary_id>2016-003867-21</secondary_id>
    <nct_id>NCT03331835</nct_id>
  </id_info>
  <brief_title>A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate added benefit of brodalumab versus a selected
      systemic comparator in treatment of moderate to severe plaque psoriasis in Germany in
      subjects who have not previously received systemic treatment for psoriasis.

      Fumaric acid esters have been selected as the comparator because it is an established
      systemic treatment of psoriasis in Germany.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 24-week, randomised, open-label, active-controlled, parallel group, multi-centre trial with
      investigator-blinded efficacy assessments
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At least 75% improvement from baseline at Week 24 in Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>baseline to Week 24</time_frame>
    <description>The PASI score grades the extent and severity of psoriatic involvement for each of four body regions (head and neck, upper extremities, trunk, and lower extremities) using a 7-point scale for extent of involvement in each body region and 5-point scales for severity of each of the clinical signs redness, thickness, and scalliness in each body region.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Static Physician's Global Assessment (sPGA) scale score of 0 or 1 at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>sPGA is a 6-point scale that represents the average lesion severity on the trunk and limbs. The assessment is based on the condition of the disease at the time of evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>At least 90% improvement from baseline at Week 24 in PASI</measure>
    <time_frame>baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100% improvement from baseline at Week 24 in PASI</measure>
    <time_frame>baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in PASI score</measure>
    <time_frame>baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI improvement (%) from baseline at Week 24</measure>
    <time_frame>baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in affected body surface area (BSA)</measure>
    <time_frame>baseline to Week 24</time_frame>
    <description>The surface area of the subject's hand (palm and fingers) is used as a reference measurement to calculate the percentage of each body region that is affected by psoriasis. One hand is approximately equal to 1% total BSA.
Furthermore, the complete body surface area (BSA=100%) can be divided into regions that approximates percentages of BSA as follows: head and neck (10%), upper extremities (20%), the trunk including the axillae and groin (30%), and finally the lower extremities, including the buttocks (40%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Symptom Inventory (PSI) responder at Week 24 (total score ≤ 8, with no item scores &gt; 1)</measure>
    <time_frame>Week 24</time_frame>
    <description>The PSI consists of eight psoriasis-specific questions. Subjects will be requested to rate the severity of their symptoms in the last 24 hours from 'not at all' to 'very severe,' ranging from 0 to 4. Total scores range from 0 to 32 with higher scores indicating worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSI total score of 0 at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of symptom-free days from randomisation to Week 24 (symptom-free day = daily total PSI of 0 on that day)</measure>
    <time_frame>baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of symptoms assessed as the normalised area under the curve (AUC) of PSI from baseline to the last available assessment</measure>
    <time_frame>baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 24 in Dermatology Life Quality Index (DLQI) total score</measure>
    <time_frame>baseline to Week 24</time_frame>
    <description>DLQI consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all ⁄not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI total score of 0 or 1 at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Brodalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kyntheum® (brodalumab) pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections. First 3 injections are administered weekly, and hereafter every two weeks (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fumaric acid esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt) Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)
Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Brodalumab</intervention_name>
    <description>Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).
Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis.</description>
    <arm_group_label>Brodalumab</arm_group_label>
    <other_name>Kyntheum®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fumaric acid esters</intervention_name>
    <description>Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.</description>
    <arm_group_label>Fumaric acid esters</arm_group_label>
    <other_name>Fumaderm®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Criteria for Inclusion:

          -  Men or women ≥18 years of age at the time of screening.

          -  Subjects with chronic plaque type psoriasis diagnosed at least 6 months before
             randomisation.

          -  Subjects with moderate to severe plaque psoriasis in whom topical therapy is not
             adequate and who are candidates for systemic therapy, defined at randomisation by PASI
             &gt;10, affected BSA &gt;10%, and DLQI &gt;10.

          -  Subject has no known history of active tuberculosis.

          -  Subject has a negative test for tuberculosis taken at screening (negative Quantiferon
             test).

          -  Subject and/or subject's designee is/are capable of administering subcutaneous
             injections.

        Main Criteria for Exclusion:

          -  Previous or current systemic treatment of plaque psoriasis or known contraindication
             for systemic therapy.

          -  Previous or current PUVA (psoralens and ultraviolet A) therapy.

          -  Washouts and non-permitted drugs:

               1. Have received phototherapy (UVA light therapy without psoralens, UVB light
                  therapy, excimer laser, tanning beds etc. within 4 weeks of baseline, or

               2. Have had topical psoriasis treatment within 2 weeks of baseline (exceptions:
                  bland emollients without urea or beta or alpha hydroxy acids)

               3. Have received any biologic immune modulating treatments used for indication other
                  than psoriasis within 4 weeks of baseline or within a period of 5 half-lives of
                  the IMP, whichever is longer

               4. Have received any other systemic immune modulating treatment (including but not
                  limited to oral retinoids, methotrexate, calcineurin inhibitors, oral or
                  parenteral corticosteroids etc. used for indications other than psoriasis) within
                  4 weeks of baseline or within a period of 5 half-lives of the IMP, whichever is
                  longer.

          -  Subjects with any of the following laboratory abnormalities at screening:

               1. Leukocyte cell count below 3×10^9/L or lymphocyte count below 0.7×10^9/L

               2. Aspartate aminotransferase (AST) or alanine transferase (ALT) &gt; 2× ULN (upper
                  level of normal limit)

               3. Absolute neutrophil count &lt; 2×10^9/L

               4. Serum creatinine &gt; ULN.

          -  History of depressive disorder within the last 2 years including current
             antidepressive treatment.

          -  Subjects with a history of suicidal behaviour (suicide attempt).

          -  Any suicidal ideation of severity 4 or 5 based on the eC-SSRS questionnaire at
             screening.

          -  A PHQ-8 score of ≥10 corresponding to moderate to severe depression at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Disclosure Specialist</last_name>
    <phone>+45 4494 5888</phone>
    <email>disclosure@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fachklinik Bad Bentheim Klinik für Dermatologie</name>
      <address>
        <city>Bad Bentheim</city>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin Klinik für Dermatologie, Venerologie und Allergologie Psoriasis Studien Zentrum</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rothhaar Studien GmbH Dermatologisches Studienzentrum</name>
      <address>
        <city>Berlin</city>
        <zip>10783</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Dr. Wildfeuer</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld Klinik für Dermatologie und Allergologie</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hauttumorzentrum Ruhr- Universität im St. Josef Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Dr. Niesmann und Dr. Othlinghaus</name>
      <address>
        <city>Bochum</city>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn (AöR) Klinik und Poliklinik für Dermatologie und Allergologie</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elbe Klinikum Buxtehude Klinik für Dermatologie</name>
      <address>
        <city>Buxtehude</city>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rosenpark Research</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Klinik und Poliklinik für Dermatologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen Hautklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Klinik für Dermatologie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derma-Study-Center-Friedrichshafen</name>
      <address>
        <city>Friedrichshafen</city>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Rotterdam &amp; Kollegen Facharzt für Haut &amp; Geschlechtskrankheiten</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45883</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SCIderm GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinik für Dermatologie Allergologie und Venerologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitäts-Hautklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Dermatologie, Venerologie und Allergologie Universitätsklinikum Schleswig-Holstein, Campus Kiel Psoriasis-Zentrum</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exellenzzentrum Entzündungsmedizin (CCIM) Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Mainz Department of Dermatology and Allergy, Clinical Research Center</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim der Universität Heidelberg Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Technische Universität München Klinik und Poliklinik für Dermatologie und Allergologie</name>
      <address>
        <city>München</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Osnabrück - Klifos</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KLINIKUM VEST GmbH Knappschaftskrankenhaus Recklinghausen Klinik für Dermatologie und Allergologie</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Weber &amp; Crainic</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Dres. Leitz</name>
      <address>
        <city>Stuttgart</city>
        <zip>70178</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center University of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis</name>
      <address>
        <city>Witten</city>
        <zip>58453</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

